Controlled iPSC Culture & Banking for Early-Phase Development of Allogeneic NK Cell Therapies

Time: 9:15 am
day: Day One


  • Limitless expansion of iPSCs allows for the early-phase manufacture of cGMP master cell banks that serve the entire product lifecycle
  • Creation of clinically relevant iPSC banks requires raw material qualification, application of cGMP principles throughout the process, and appropriate testing strategies
  • Gene-edited iPSCs cultured in adherent systems can be differentiated into hematopoietic progenitors and hypo-immune effector cells in a myriad of bioprocessing systems